The first known “trifunctional” 5-HT2C receptor agonist that is also a full antagonist of the 5-HT2A and 5-HT2B receptors, creating an exciting drug lead for multiple neuropsychiatric disorders.
PRESS RELEASE | OCTOBER 5, 2023
PRESS RELEASE | OCTOBER 5, 2023
The first known “trifunctional” 5-HT2C receptor agonist that is also a full antagonist of the 5-HT2A and 5-HT2B receptors, creating an exciting drug lead for multiple neuropsychiatric disorders.
